Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    01070914
Previous Study | Return to List | Next Study

Early Detection and Characterization of Primary Ciliary Dyskinesia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01070914
Recruitment Status : Unknown
Verified May 2012 by Ziv Hospital.
Recruitment status was:  Recruiting
First Posted : February 18, 2010
Last Update Posted : May 8, 2012
Sponsor:
Collaborators:
Rambam Health Care Campus
Hadassah Medical Organization
Tel-Aviv Sourasky Medical Center
Sheba Medical Center
Assaf-Harofeh Medical Center
The Nazareth Hospital, Israel
Soroka University Medical Center
Shaare Zedek Medical Center
Schneider Children's Medical Center, Israel
Information provided by (Responsible Party):
Ziv Hospital

Brief Summary:
Primary Ciliary Dyskinesia (PCD) is a severe genetic disorder caused by various mutations in genes affecting ciliary motility. Various new and complementary diagnostic techniques, including measurements of nasal nitric oxide (NO), Video Microscopy (VM), Immunoflourescence (IF) and genetic analysis have recently been recognized as simpler and more accurate modalities for the diagnosis and characterization of patients with PCD compared to electron microscopy. While considered a rare disease worldwide, PCD is more prevalent among highly consanguineous populations, such as those found in Israel. We hypothesize that using modern state of the art and novel test modalities on a national scale in Israel will improve diagnosis, improve phenotypic-genotypic correlations and create a national registry for PCD.

Condition or disease
Primary Ciliary Dyskinesia

Detailed Description:

Primary Ciliary Dyskinesia (PCD) is a severe genetic disorder caused by various mutations in genes affecting ciliary motility. While diagnosis of PCD in Israel is currently based for the most part on electron microscopy (EM) detection of ciliary ultrastructural defects, this technique may be unsatisfactory and does not overcome the inherent heterogeneity. Thus, late and under-diagnosis and suboptimal characterization of patients is common. Various newer and complementary diagnostic techniques, including measurements of nasal nitric oxide (NO), Video Microscopy (VM), Immunoflourescence (IF) and genetic analysis have recently been recognized as simpler and more accurate modalities for the diagnosis and characterization of patients with PCD. While considered a rare disease worldwide, PCD is more prevalent among highly consanguineous populations, such as those found in Israel. Given the rarity of cases particularly familial ones, the most useful implementation of new diagnostic techniques requires multicenter collaboration.

We hypothesize that using modern state of the art and novel test modalities on a national scale in Israel will improve diagnosis, improve phenotypic-genotypic correlations and create a national registry for PCD.

We propose to perform such a multicenter study whose aims are:

  • To characterize the complex phenotype and genotype of PCD in Israel, using state-of-the-art and novel diagnostic techniques.
  • To create a national registry of patients and families with PCD in Israel
  • To develop robust national standards of diagnosis and evaluation, which will lead to better and earlier diagnosis, treatment and counseling.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 130 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: The Israeli National Consortium for Early Detection and Characterization of Primary Ciliary Dyskinesia
Study Start Date : June 2011
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : June 2013





Primary Outcome Measures :
  1. Phenotypic and genetic characterization [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Residents of Israel
Criteria

Inclusion Criteria:

  • Patients with PCD diagnosis
  • Subjects with suspected diagnosis of PCD

Exclusion Criteria:

  • Subjects Uncooperative with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01070914


Contacts
Layout table for location contacts
Contact: Israel Amirav, MD 97246828712 amirav@012.net.il

Locations
Layout table for location information
Israel
Ziv Medical center Recruiting
Safed, Israel, 13100
Principal Investigator: Israel Amirav, MD         
Sponsors and Collaborators
Ziv Hospital
Rambam Health Care Campus
Hadassah Medical Organization
Tel-Aviv Sourasky Medical Center
Sheba Medical Center
Assaf-Harofeh Medical Center
The Nazareth Hospital, Israel
Soroka University Medical Center
Shaare Zedek Medical Center
Schneider Children's Medical Center, Israel
Investigators
Layout table for investigator information
Principal Investigator: Israel Amirav, MD Ziv Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ziv Hospital
ClinicalTrials.gov Identifier: NCT01070914    
Other Study ID Numbers: Hackmon-2
First Posted: February 18, 2010    Key Record Dates
Last Update Posted: May 8, 2012
Last Verified: May 2012
Keywords provided by Ziv Hospital:
Cilia
Phenotyping
Diagnosis
Nitric Oxide
Bronchiectasis
Additional relevant MeSH terms:
Layout table for MeSH terms
Ciliary Motility Disorders
Kartagener Syndrome
Dyskinesias
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Ciliopathies
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn
Bronchiectasis
Bronchial Diseases
Respiratory System Abnormalities
Dextrocardia
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Situs Inversus